A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients
Neuro-Oncology · 2024
DOI: 10.1093/neuonc/noae142 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Mary Jane Lim-Fat und 28 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada (M.J.L.-F.). Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Mutation, Brain Neoplasms, Glioma. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Boston Children's Hospital Faculty Career Development Fellowship, Boston Children’s Hospital Faculty Career Development Fellowship.
Abstract (Originalsprache)
Background
The frequency and significance of IDH mutations in glioma across age groups are incompletely understood. We performed a multi-center retrospective age-stratified comparison of patients with IDH-mutant gliomas to identify age-specific differences in clinico-genomic features, treatments, and outcomes.
Methods
Clinical, histologic, and sequencing data from patients with IDH-mutant, grades 2–4 gliomas, were collected from collaborating institutions between 2013 and 2019. Patients were categorized as pediatric (<19 years), young adult (YA; 19–39 years), or older adult (≥40 years). Clinical presentation, treatment, histologic, and molecular features were compared across age categories using Fisher’s exact test or analysis-of-variance. Cox proportional-hazards regression was used to determine the association of age and other covariates with overall (OS) and progression-free survival (PFS).
Results
We identified a cohort of 379 patients (204 YA) with IDH-mutant glioma with clinical data. There were 155 (41%) oligodendrogliomas and 224 (59%) astrocytomas. YA showed significantly shorter PFS and shorter median time-to-malignant transformation (MT) compared to pediatric and adult groups, but no significant OS difference. Adjusting for pathology type, extent of resection, and upfront therapy in multivariable analysis, the YA group was independently prognostic of shorter PFS than pediatric and adult groups. Among astrocytomas, CDK4/6 copy number amplifications were associated with both shorter PFS and shorter OS. Among oligodendrogliomas, PIK3CA and CDKN2A/2B alterations were associated with shorter OS.
Conclusions
IDH-mutant glioma YA patients had significantly shorter PFS and time to MT but did not differ in OS compared to pediatric and adult groups. Treatment approaches varied significantly by patient age and warrant further study as addressable age-associated outcome drivers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada (M.J.L.-F.).
- Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California, USA.
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.
- Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Jennifer A Cotter, Mehdi Touat, Joseph Driver, Ashley S Margol, Katherine E Warren, Wenya Linda Bi, David A Reardon, Kee Kiat Yeo
Förderung
- NCI NIH HHS
- Boston Children's Hospital Faculty Career Development Fellowship
- Boston Children’s Hospital Faculty Career Development Fellowship
Zitieren
APA
Lim-Fat, M. J., Cotter, J. A., Touat, M., Vogelzang, J., Sousa, C., Pisano, W., Geduldig, J., Bhave, V., Driver, J., Kao, P. C., McGovern, A., Ma, C., Margol, A. S., Cole, K., Smith, A., Goldman, S., Kaneva, K., Truong, A., Nazemi, K. J., …, & Yeo, K. K. (2024). A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae142
Vancouver
Lim-Fat MJ, Cotter JA, Touat M, Vogelzang J, Sousa C, Pisano W, et al. A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients. Neuro-Oncology. 2024. doi:10.1093/neuonc/noae142
BibTeX
@article{LimFat2024,
author = {Lim-Fat, Mary Jane and Cotter, Jennifer A and Touat, Mehdi and Vogelzang, Jayne and Sousa, Cecilia and Pisano, Will and Geduldig, Jack and Bhave, Varun and Driver, Joseph and Kao, Pei-Chi and McGovern, Alana and Ma, Clement and Margol, Ashley S and Cole, Kristina and Smith, Amy and Goldman, Stewart and Kaneva, Kristiyana and Truong, AiLien and Nazemi, Kellie J and Wood, Matthew D and Wright, Karen D and London, Wendy B and Warren, Katherine E and Wen, Patrick Y and Bi, Wenya Linda and Alexandrescu, Sanda and Reardon, David A and Ligon, Keith L and Yeo, Kee Kiat},
title = {A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients},
journal = {Neuro-Oncology},
year = {2024},
doi = {10.1093/neuonc/noae142}
}
EUVIMED